Liminatus Pharma Executes 1-for-50 Reverse Split to Regain Nasdaq Compliance
LIMN is trading near its 52-week low of $0.095 (14% above the low) on light trading volume (0.1× avg).
Summary
Liminatus Pharma announced a 1-for-50 reverse stock split effective August 20, 2026, with split-adjusted trading beginning August 21. The move is aimed at regaining Nasdaq compliance after the company received a delisting notice and was denied a second extension. The reverse split will reduce the number of outstanding shares and increase the per-share price, but it does not change the company's market capitalization. This follows a series of financial distress signals, including going concern doubt, material weaknesses, and a cash balance of only $3.0 million as of the latest 10-Q. The split is a critical step to avoid delisting, but it also reflects the company's ongoing struggle to meet exchange requirements.
At the time of this announcement, LIMN was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.10 to $4.12. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.